Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002022680 - SITE-SPECIFIC, ANTIBODY-MEDIATED ACTIVATION OF PROAPOPTOTIC CYTOKINE: AMAICE (ANTIBODY-MEDIATED APOPTOSIS INDUCING CYTOKINE)

Publication Number WO/2002/022680
Publication Date 21.03.2002
International Application No. PCT/EP2001/010364
International Filing Date 07.09.2001
Chapter 2 Demand Filed 11.04.2002
IPC
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 14/525 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
525Tumour necrosis factor (TNF)
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
CPC
A61K 47/6899
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6891Pre-targeting systems involving an antibody for targeting specific cells
6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • PFIZENMAIER, Klaus [DE]/[DE]
  • WAJANT, Harald [DE]/[DE]
  • MOOSMAYER, Dieter [DE]/[DE] (UsOnly)
  • WÜEST, Thomas [CH]/[CH] (UsOnly)
Inventors
  • PFIZENMAIER, Klaus
  • WAJANT, Harald
  • MOOSMAYER, Dieter
  • WÜEST, Thomas
Agents
  • GRAF VON STOSCH, Andreas
Priority Data
100 45 591.315.09.2000DE
Publication Language German (DE)
Filing Language German (DE)
Designated States
Title
(DE) ORTSSPEZIFISCHE, ANTIKÖRPERVERMITTELTE AKTIVIERUNG PROAPOPTOTISCHER ZYTOKINE: AMAIZe (ANTIBODY-MEDIATED APOPTOSIS INDUCING ZYTOKINE)
(EN) SITE-SPECIFIC, ANTIBODY-MEDIATED ACTIVATION OF PROAPOPTOTIC CYTOKINE: AMAICE (ANTIBODY-MEDIATED APOPTOSIS INDUCING CYTOKINE)
(FR) ACTIVATION LOCALEMENT SPECIFIQUE, PAR L'INTERMEDIAIRE D'ANTICORPS, D'UNE ZYTOKINE PRO-APOPTOSE : AMAIZE (ANTIBODY-MEDIATED APOPTOSIS INDUCING ZYTOKINE)
Abstract
(DE)
Gegenstand der Erfindung sind Antikörper-Zytokin-Fusionsproteine mit proapoptotischen und immunmodulierenden Eigenschaften, aber a priori sehr niedriger bzw. auf bestimmte Rezeptorsubtypen eingeschränkter spezifischer Bioaktivität im Zytokinanteil. Diese Reagenzien entfalten erst nach Antikörper-vermittelter Bindung des Fusionsproteins an ein spezifisches, zellmembranexprimiertes Zielmolekül die volle biologische Wirkung über den/die entsprechenden Zytokinrezeptoren. Durch geeignete Auswahl der Antikörperspezifität wird die Zytokin-Aktivität auf das zu behandelnde Gewebe, z.B. Tumorgewebe, gerichtet und es kann ein auf die jeweilige Indikation/Tumorentität spezifisch abgestimmtes/optimiertes Therapeutikum hergestellt werden.
(EN)
The invention relates to antibody-cytokine fusion proteins having proapoptotic and immunomodulating properties, however, a priori having a specific bioactivity in the cytokine portion that is very low or limited to certain receptor subtypes. These reagents first deploy the full biological action over the corresponding cytokine receptor(s) after an antibody-mediated binding of the fusion protein to a specific, cell membrane-expressed target molecule. By appropriately selecting the antibody specificity, the cytokine activity is directed at the tissue to be treated, e.g. tumor tissue, and a therapeutic agent can be produced, which is specifically matched to/optimized for the respective indication/tumor entity.
(FR)
L'invention a pour objet des protéines de fusion anticorps-zytokine à propriétés pro-apoptoses et à modulation de l'immunité, présentant toutefois, dans la fraction zytokine, une bioactivité spécifique a priori très faible, éventuellement limitée à des sous-types de récepteurs déterminés. Ces réactifs ne développent leur pleine action biologique sur les récepteurs de zytokine correspondants, qu'après liaison, par l'intermédiaire d'anticorps, de la protéine de fusion sur une molécule cible spécifique, exprimée par une membrane cellulaire. Par un choix approprié de la spécificité des anticorps, l'activité de la zytokine est dirigée sur le tissu à traiter, par exemple, un tissu tumoral, offrant ainsi la possibilité de fabriquer un agent thérapeutique adapté/optimisé spécifiquement sur l'indication/entité tumorale respective.
Latest bibliographic data on file with the International Bureau